Advanced Filters
noise

Scleroderma Clinical Trials

A listing of Scleroderma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 145 clinical trials

Hormonal, Metabolic, and Signaling Interactions in PAH

Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.

- 90 years of age All Phase N/A

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.

18 - 85 years of age All Phase N/A
C CoRDS Team

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures …

years of age All Phase N/A
A Aurélien GUFFROY, MD

Familial Systemic Scleroderma

Studying familial forms of systemic scleroderma offers several advantages: To better understand the pathophysiology of a complex autoimmune disease based on "extreme" cases (familial forms); To identify potential molecular markers predictive of disease progression; To identify potential pathophysiological targets for developing new therapies, particularly relevant in severe and refractory forms …

18 years of age All Phase N/A

Diffuse Cutaneous Scleroderma (DSSc) SFDI Study

Scleroderma (SSc) is an autoimmune disease characterized by fibrosis (or collagen deposition) of the skin and internal organs. The extent of skin fibrosis is an important predictor of internal organ complications and increased mortality. Currently a very imprecise, subjective method that varies amongst different doctors for the same patient is …

18 years of age All Phase N/A
E Eliza Pelrine, BA

Scleroderma Registry & Repository at the Hospital for Special Surgery

The overall objective of the Scleroderma Registry is to support and promote the basic science and clinical research of this complex rheumatic disease at the Hospital for Special Surgery (HSS). The registry facilitates our understanding of the clinical features, pathobiology, genetics of Scleroderma. This will ultimately lead to a potential …

18 years of age All Phase N/A
D Dezeray Cephas Dutton

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.

18 years of age All Phase 2
S Songul B Yentur

Connective Tissue Massage in Scleroderma

The only study in the literature that examined connective tissue massage in patients with scleroderma is by Bongi et al. In this study, connective tissue massage and Mc Mennell joint manipulation technique were applied to the experimental group in addition to the home exercise program. The control group was offered …

18 - 65 years of age All Phase N/A
S Songul B Yentur

Respiratory Muscle Strength and Aerobic Capacity in Scleroderma

Primary aim of this study was to compare respiratory muscle strength, aerobic capacity, dyspnea, pulmonary function tests and fatigue values with healthy controls. The secondary aim was to evaluate the relationship between respiratory muscle strength and other parameters in these patients and to examine the factors that may affect respiratory …

18 - 65 years of age Female Phase N/A
T Tracy Luckhardt

Platform Clinical Study for Conquering Scleroderma

The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.

18 years of age All Phase 2

Simplify language using AI